The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksTime Finance Regulatory News (TIME)

Share Price Information for Time Finance (TIME)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 39.75
Bid: 39.00
Ask: 40.50
Change: 0.00 (0.00%)
Spread: 1.50 (3.846%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 39.75
TIME Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

New LTIP & Director/PDMR Shareholding

22 Jul 2022 07:00

RNS Number : 4213T
Time Finance PLC
22 July 2022
 

22 July 2022

 

Time Finance plc

("Time Finance", the "Group" or the "Company")

 

 

New Long Term Incentive Plan

 

Director/PDMR Shareholding

 

Time Finance plc, the AIM listed specialist finance provider announces the establishment of a 2022 Share Option Scheme (the "2022 Option Scheme" or the "Scheme"). The 2022 Option Scheme has been designed to incentivise and retain the Company's executives and senior management to deliver sustainable growth for the Company's shareholders and any options awarded under the 2022 Option Scheme are expected to be satisfied without further dilution for the Group's shareholders. The Group also announces awards of share options under the 2022 Option Scheme as set out below.

 

2022 Share Option Scheme

 

The Company has established the 2022 Option Scheme as an unapproved (i.e. non tax-advantaged) share option scheme under which nil-cost options over ordinary shares of 10 pence each in the capital of the Company ("Options") may be awarded. Options awarded under the 2022 Option Scheme will be subject to a three-year vesting period from the date of grant, with the number of awards which ultimately vest dependent on the grantee's continued service and on stretching performance conditions set by the Time Finance Remuneration Committee.

 

The Options today awarded under the 2022 Option Scheme, details of which are provided below, are the only Options that will be awarded under the Scheme. No future Option awards will be made under the 2022 Option Scheme.

 

As a result, it is currently expected that the Options awarded under the 2022 Option Scheme will be capable of being satisfied in full from unallocated existing ordinary shares held by the Company's Employee Benefit Trust, without any further dilutionary effect.

 

The sale of ordinary shares acquired pursuant to exercises of Options will not be permitted for a period of 12 months, save for sales of ordinary shares to meet the income tax and both the employee and employer National Insurance liabilities on exercise, subject to orderly market and closed period restrictions. The sale of ordinary shares in the ensuing period of 12 months will be permitted subject to orderly market and close period restrictions.

 

Following the implementation of the 2022 Share Option Scheme, no further share options will be awarded under the Company's 2020 Share Option Scheme, details of which were announced by the Company on 29 October 2020 (the "2020 Option Scheme"). 405,000 unvested share options remain in issue under the 2020 Option Scheme.

 

Share Option Awards

 

Under the 2022 Option Scheme, the Company has today granted a total of 1,835,000 Options (the "Awarded Options"), representing 1.98 per cent. of the Company's current undiluted issued ordinary share capital.

 

The Awarded Options will vest in three equal tranches over a three-year period subject to stretching annual performance conditions in respect of the profitability of the Group over the three years ended 31 May 2025 and to Remuneration Committee discretion.

 

Vested Awarded Options may be exercised at nil-cost from the date of vesting up until the date falling 5 years from the date of vesting, provided that the recipient remains an employee of the Group at the date that the Awarded Options are exercised.

 

Of the Awarded Options, 1,235,000 Awarded Options have been granted to Ed Rimmer, the Company's Chief Executive Officer and the remaining 600,000 Awarded Options have been granted to PDMR's of the Group. The notifications below, provided in accordance with the Market Abuse Regulation, provide further details.

 

 

For further information, please contact:

 

Time Finance plc

Ed Rimmer, Chief Executive Officer

01225 474230

James Roberts, Chief Financial Officer

01225 474230

Cenkos Securities plc (NOMAD and Broker)

Ben Jeynes / Max Gould (Corporate Finance)

Julian Morse (Sales)

0207 397 8900

Walbrook PR

0207 933 8780

Paul Vann /Joseph Walker

07768 807631

Timefinance@walbrookpr.com

 

 

 

About Time Finance:

Time Finance's core strategy is to focus on providing or arranging the finance UK SMEs require to fund their businesses. It offers a multi-product range for SMEs including asset, vehicle, loan and invoice finance. While primarily an 'own-book' lender the Group does operates a 'hybrid' lending and broking model enabling it to optimize business levels through market and economic cycles.

 

More information is available on the Company website www.timefinance.com.

 

 

 

The information below is disclosed in accordance with Article 19 of the EU Market Abuse Regulation.

 

1 

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

1) Ed Rimmer

2) Steve Nichols

3) Sharon Bryden

 

2

Reason for the notification

a)

Position/status

1) Chief Executive Officer

2) PDMR

3) PDMR

 

 

b)

Initial notification /Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a) 

Name

Time Finance plc

b)

LEI

213800VG3QJGBP2MKR86

 

 

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

 

Description of the financial instrument, type of instrument

 Identification code

Ordinary Shares of 10p each

 

ISIN: GB00BCDBXK43

 

 

b)

Nature of the transaction

Award of nil-cost share options

 

 

c)

Price(s) and volume(s)

 

 

 

Price(s)

Volume(s)

1) nil

2) nil

3) nil

 

1,235,000

300,000

300,000

 

d)

Aggregated information

- Aggregated volume

- Price

 

 n/a single transactions

 

 

e)

Date of the transaction

1) 21 July 2022

2) 21 July 2022

3) 21 July 2022

 

 

f)

Place of the transaction

Outside of a trading venue

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DSHSEISIEEESELW
Date   Source Headline
3rd Apr 20247:00 amRNSExtended & Improved £64m Funding Facility
26th Mar 20247:00 amRNSQ3 Trading Update
5th Mar 20247:00 amRNSNotice of Trading Update
25th Jan 20247:00 amRNSInterim Results
18th Jan 20244:30 pmRNSHolding(s) in Company
19th Dec 20237:00 amRNSHalf-Year Trading Update & Notice of Results
21st Nov 20237:00 amRNSExercise of Options & Director/PDMR Shareholding
15th Nov 202312:54 pmRNSChange of Nominated Adviser & Corporate Broker
9th Nov 20237:00 amRNSTrading Update
7th Nov 202311:45 amRNSResult of AGM
23rd Oct 20238:30 amRNSDirector Share Purchase
19th Oct 20237:00 amRNSDirector Share Purchase
11th Oct 20237:00 amRNSDirector Share Purchases
3rd Oct 20237:00 amRNSDirector/PDMR Shareholdings: Vesting of Options
27th Sep 20238:30 amRNSNotice of AGM
26th Sep 20237:00 amRNSQ1 Trading Update
26th Sep 20237:00 amRNSFinal Results
19th Sep 20237:00 amRNSAppointment of Independent Non-Executive Directors
12th Sep 20237:00 amRNSOwn-Book Update, Notice of Results, Pres & AGM
11th Jul 20237:00 amRNSDirector Share Purchase
29th Jun 20237:00 amRNSFull Year Trading Update
24th May 20239:04 amRNSDelivery of First Asset-Based Lending Facility
3rd May 20237:00 amRNSTrading Update & Notice of Final Results
8th Mar 20237:00 amRNSQ3 Trading Update: Pre-Tax Profits up 172%
9th Feb 202311:40 amRNSHolding in Company
26th Jan 202311:05 amRNSSecond Price Monitoring Extn
26th Jan 202311:00 amRNSPrice Monitoring Extension
26th Jan 20237:00 amRNSInterim Results
20th Dec 20221:24 pmRNSExercise of Options & Director/PDMR Shareholding
16th Dec 20227:00 amRNSH1 Trading Update & Notice of Interim Results
14th Nov 20227:00 amRNSDirector Share Purchases
3rd Nov 20227:00 amRNSMelloLondon Investor Conference
31st Oct 20222:00 pmRNSResult of AGM
19th Oct 20227:00 amRNSOwn Book Lending Portfolio reaches record £145m
5th Oct 20227:00 amRNSDirector Share Purchase
4th Oct 202212:00 pmRNSDirector/PDMR Shareholding
23rd Sep 20222:15 pmRNSNotice of AGM
22nd Sep 20227:00 amRNSQ1 Trading Update
22nd Sep 20227:00 amRNSFinal Results for the year ended 31 May 2022
15th Sep 20227:00 amRNSNotice of Results & Q1 Update and Presentation
6th Sep 20227:00 amRNSAppointments Strengthen Asset Finance Division
22nd Jul 20227:00 amRNSNew LTIP & Director/PDMR Shareholding
19th Jul 20227:02 amRNSDirector Share Purchases
18th Jul 20227:00 amRNSDirector Share Purchase
7th Jul 20227:00 amRNSTrading Update & Notice of Final Results
10th Jun 20227:00 amRNSNotice of Trading Update and Investor Presentation
5th May 20229:19 amRNSHolding in Company
27th Apr 20223:28 pmRNSHolding in Company
27th Apr 202212:51 pmRNSHolding in Company
26th Apr 20223:30 pmRNSTR-1 Holding in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.